Medicine Today Internal Medicine Webcast Series

Hepatitis C Management:

References

  1. Armstrong GL, Wasley AM, Simard EP, et al. Prevalence of hepatitis C virus infection in the Unites States, 199 through 2002. Ann Intern Med 2006;144:705-14.
  2. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis — United States, 2006. MMWR 2008;57:No. SS-2.
  3. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
  4. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
  5. Koff R, Younossi Z, Reddy R, Shiffman M. Debate: hepatitis C with normal liver enzymes: to treat or not to treat. Am J Gastroenterol 2004;99:972-976.
  6. Shiffman ML, Diago M, Tran A, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006;4:645-652.
  7. Anonymous. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2007.
  8. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:1-13, 15; quiz CE11-14.
  9. Pawlotsky JM. Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics. Semin Liver Dis 2003;23 Suppl 1:3-11.
  10. Castelain S, Descamps V, Thibault V, et al. TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol 2004;31:227-234.
  11. Hadziyannis E, Hadziyannis A, Yen-Lieberman B, et al. Hepatitis C virus RNA assays: a comparison of SuperQuant and Monitor. J Clin Gastroenterol 2001;33:45-48.
  12. Fang JW, Chow V, Lau JY. Virology of hepatitis C virus. Clin Liver Dis 1997;1:493-514.
  13. Narasimhan G, Sargios TN, Kalakuntla R, et al. Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat 2006;13:783-786.
  14. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
  15. Brunetti E, Silini E, Pistorio A, et al. Coarse vs fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis. J Hepatol 2004;40:501-6.
  16. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosis of advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997;92:1302-4.
  17. Kettaneh A, Marcellin P, Douvin C, Poupon R, Ziol M, Beaugrand M, de Ledinghen V. Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients. J Hepatol 2006.
  18. Posthouwer D, Mauser-Bunschoten EP, Fischer K, et al. Significant liver damage in patients with bleeding disorders and chronic hepatitis C: non-invasive assessment of liver fibrosis using transient elastography. J Thromb Haemost 2007;5:25-30.
  19. Castera L, Foucher J, Bertet J, Couzigou P, de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 2006;43:373-374; author reply 375-376.
  20. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005;42:838-845.
  21. Health. NIo. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C:. Hepatology 2002;36:S3-20.
  22. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998;27:1730-1735.
  23. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-809.
  24. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004;39:826-834.
  25. Chen CM, Yoon YH, Yi HY, Lucas DL. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcohol Clin Exp Res 2007;31:285-292.
  26. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
  27. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
  28. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
  29. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231.
  30. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2a. Gastroenterology 2001;120:1438-1447.
  31. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000;182:28-35.
  32. Lam AM, Frick DN. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J Virol 2006;80:404-411.
  33. Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003;38:509-517.
  34. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003;37:1351-1358.
  35. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652.
  36. Organization WH. Hepatitis C surveillance and control. Available at: http://www.who.int/publications/en/. Accessed: July 31, 2008.
  37. Armstrong GL, Wasley AM, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
  38. Centers for Disease Control and Prevention. Recommendations for the prevention and control of hepatitis C virus infection and HCV-related chronic disease. MMWR 1998;47(RR-19):1-39.
  39. Michelin BD, Muller Z, Stelzl E, Marth E, Kessler HH. Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol 2007;38:96-100.
  40. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.
  41. DiBisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
  42. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, et al, for the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
  43. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1139-1146.
  44. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-598.
  45. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-966.
  46. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
  47. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-1499.
  48. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
  49. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
  50. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
  51. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002;36:S121-127.
  52. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46:78-84.
  53. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007;46:1688-1694.
  54. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
  55. Sanyal AJ. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications. Aliment Pharmacol Ther 2005;22 Suppl 2:48-51.
  56. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
  57. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002;36:S128-134.
  58. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-1023; discussion 1947.
  59. Shiffman ML. Management options in nonresponders to previous HCV therapy. London: Science Press. 2004:122-125.
  60. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005;39:S23-27.
  61. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-1458.
  62. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;44:1598-1606.
  63. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-2499.
  64. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-1311.
  65. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003;37:1343-1350.
  66. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T, for the Consensus Interferon Study Group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30:787-793.
  67. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J, for the International Hepatitis Interventional Therapy Group. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-1323.
  68. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatoloty 2004;39:1702-1708.
  69. Muir AJ, Bornstein JD, Killenberg PG, for the Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatmetn of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350;2265-2271.
  70. Metwally MA, Zein CO, Zein NN. Regression of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C treated with interferon-based therapy. Gastroenterology 2003;124:1561.
  71. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355.
  72. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003;9:905-915.
  73. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-262.
  74. Charlton M, Wiesner R. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis 2004;24 Suppl 2:79-88.
  75. Charlton M. Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep 2007;9:23-30.
  76. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
  77. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
  78. Baltz AC, Trotter JF. Living donor liver transplantation and hepatitis C. Clin Liver Dis 2003;7:651-665, viii.
  79. Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004;10:340-346.
  80. Forman LM, Trotter JF, Emond J. Living donor liver transplantation and hepatitis C. Liver Transpl 2004;10:347-348.
  81. Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20:773-779.
  82. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995;22:1084-1089.
  83. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002;8:1000-1006.
  84. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004;77:190-194.
  85. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004;78:1303-1307.
  86. Neff GW, O'Brien CB, Cirocco R, et al. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl 2004;10:595-598.
  87. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-838.
  88. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl 2003;9:S95-S100.
  89. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8:S19-27.
  90. Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004;10:52-57.
  91. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003;9:1159-1165.
  92. Stravitz RT, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004;10:850-858.
  93. Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004;10:859-867.
  94. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002;36:S201-209.
  95. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-569.
  96. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-Infected Person. Ann Intern Med 2003;138:197-207.
  97. Martagon J, Gordon SM. Special management challenges in hepatitis C. Cleve Clin J Med 2003;70 Suppl 4:S27-33.
  98. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996;23:585-591.
  99. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. Aids 2003;17:1023-1028.
  100. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
  101. Chung RT, Andersen J, Volberding P, et al, for the AIDS Clinical Trials Group A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribaviring for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
  102. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007;39:2-17.
  103. McGuire BM, Julian BA, Bynon JS, Jr, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006;144:735-741.
  104. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3-10.
  105. Carithers RL, Jr. Hepatitis C and renal failure. Am J Med 1999;107:90S-94S.
  106. Huang CC. Hepatitis in patients with end-stage renal disease. J Gastroenterol Hepatol 1997;12:S236-241.
  107. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999;106:347-354.
  108. Furusyo N, Hayashi J, Kanamoto-Tanaka Y, Ariyama I, Etoh Y, Shigematsu M, Kashiwagi S. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci 2000;45:2221-2228.
  109. Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin Gastroenterol Hepatol 2005;3:S113-117.
  110. Ramamurthy M, Muir AJ. Treatment of hepatitis C in special populations. Clin Liver Dis 2006;10:851-865.
  111. Mendez-Sanchez N. Treatment of hepatitis C virus infection and renal disease. Ann Hepatol 2006;5 Suppl 1:53-55.
  112. Izopet J, Rostaing L, Sandres K, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000;181:852-858.
  113. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998;66:471-476.
  114. Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006;20:677-683.
  115. Manga Sahin G, Sahin S, Kantarci G, Ergin H. Impact of hepatitis C virus infection on patient and graft survival in kidney transplantation. Transplant Proc 2006;38:499-501.
  116. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997;29:608-614.
  117. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995;60:799-805.
  118. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999;14:2704-2709.
  119. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999;31:2887-2889.
  120. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002;36:S93-98.
  121. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71.
  122. Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol 2006;18:1057-1063.
  123. de la Fuente L, Brugal MT, Domingo-Salvany A, Bravo MJ, Neira-Leon M, Barrio G. More than thirty years of illicit drugs in Spain: a bitter story with some messages for the future [in Spanish]. Rev Esp Salud Publica 2006;80:505-520.
  124. Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004;38:705-709.
  125. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
  126. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-644.
  127. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 1997;42:178-185.
  128. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
  129. McCullough AJ. Obesity and its nurturing effect on hepatitis C. Hepatology 2003;38:557-559.
  130. Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995;2:39-45.
  131. Park JS, Saraf N, Dieterich DT. HBV plus HCV, HCV plus HIV, HBV plus HIV. Curr Gastroenterol Rep 2006;8:67-74.
  132. Ibarra RT. Treatment of HBV-HCV coinfection. Ann Hepatol 2006;5 Suppl 1:49-52.
  133. Marcellin P. Advances in therapy for chronic hepatitis B. Semin Liver Dis 2002;22 Suppl 1:33-36.
  134. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-1732.
  135. Tovo PA, Newell ML. Hepatitis C in children. Curr Opin Infect Dis 1999;12:245-250.
  136. National Institutes of Health. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
  137. Rumbo C. Hepatitis C: current approaches in pediatrics. Pediatr Transplant 2005;9:662-665.
  138. Yazdanpanah Y, De Carli G, Migueres B, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 2005;41:1423-1430.
  139. Beekmann SE, Henderson DK. Protection of healthcare workers from bloodborne pathogens. Curr Opin Infect Dis 2005;18:331-336.
  140. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-29.
  141. Williams R. Global challenges in liver disease. Hepatology 2006;44:521-526.
  142. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.
  143. Ramadori G, Meier V. Hepatitis C virus infection: 10 years after the discovery of the virus. Eur J Gastroenterol Hepatol 2001;13:465-471.
  144. Okita K. Clinical aspects of hepatocellular carcinoma in Japan. Intern Med 2006;45:229-233.
  145. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413-415.
  146. Sherman M. Chronic hepatitis C and screening for hepatocellular carcinoma. Clin Liver Dis 2006;10:735-752.
  147. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006;25:3848-3856.
  148. Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA. Living with chronic hepatitis C means 'you just haven't got a normal life any more'. Chronic Illn 2006;2:121-131.
  149. Zickmund SL, Bryce CL, Blasiole JA, Shinkunas L, LaBrecque DR, Arnold RM. Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. Eur J Gastroenterol Hepatol 2006;18:381-388.
  150. Lim JK, Cronkite R, Goldstein MK, Cheung RC. The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life. J Clin Gastroenterol 2006;40:528-534.
  151. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006;44:491-498.
  152. Carlat DJ. The psychiatric review of symptoms: a screening tool for family physicians. Am Fam Physician 1998;58:1617-1624.
  153. Horsmans Y. Interferon-induced depression in chronic hepatitis C. J Antimicrob Chemother 2006;58:711-713.
  154. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-947.
  155. Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am 2004;33:S35-50.
  156. Weaver MF, Cropsey KL, Fox SA. HCV prevalence in methadone maintenance: self-report versus serum test. Am J Health Behav 2005;29:387-394.
  157. Fischer B, Reimer J, Firestone M, Kalousek K, Rehm J, Heathcote J. Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions. Eur J Gastroenterol Hepatol 2006;18:1039-1042.

 

 
Copyright © 2000-2017 The Cleveland Clinic Foundation. All Rights Reserved.
Center for Continuing Education | 1950 Richmond Road, TR204, Lyndhurst, OH 44124
Copyright © 2000-2017 The Cleveland Clinic Foundation. All Rights Reserved.
Center for Continuing Education | 1950 Richmond Road, TR204, Lyndhurst, OH 44124